Dataset from A Phase 1/2, Randomized, Observer-blind, Controlled, Multi-center, Dose-escalation Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A), When Administered Intramuscularly According to a 0, 1-month Schedule to RSV-seropositive Infants Aged 12 to 23 Months

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of the
respiratory syncytial virus (RSV) candidate vaccine when first administered via intramuscular
(IM) injection according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 23
months.